The ACR/CHEST ILD Guidelines in Practice: Register Now for This Informative Webinar

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Rheumatoid Arthritis

FDA Discussed 2021 Drug Warnings & Approvals at ACR Annual Meeting

  |  

ACR Convergence 2021—The recent Boxed Warning requirement applied to three Janus kinase (JAK) inhibitors, cautioning doctors and patients about several major risks in patients with rheumatoid arthritis, came only after rigorous data collection and careful consideration of the risks and the benefits, U.S. Food & Drug Administration (FDA) officials said in November at ACR Convergence…

Clinical Rheumatology Year in Review 2021

  |  

ACR Convergence 2021—On Nov. 5, Karen H. Costenbader, MD, MPH, professor of medicine, Harvard Medical School, and director of the lupus program, Brigham and Women’s Hospital, Boston, gave a whirlwind review of the most important clinical rheumatology publications of the past year. Testing New Medications for Rheumatic Disease ADVOCATE Trial of Avacopan Dr. Costenbader first…

Passive Exposure to Smoking May Increase Rheumatoid Arthritis Risk

Katie Robinson  |  

EULAR—Passive exposure to smoking during childhood or adulthood increases the risk of developing rheumatoid arthritis (RA), according to a large prospective cohort study of healthy French women presented during EULAR’s 2021 virtual European Congress of Rheumatology. Moreover, the association was mainly observed among women who had themselves never smoked.1 “In this study, we found an…

New Africa / shutterstock.com

A Rheumatologist & Pulmonologist Discuss RA-ILD

Joshua Solomon, MD, & Paul F. Dellaripa, MD  |  

Introduction The understanding and treatment of rheuma­toid arthritis (RA) has evolved dramatically in the past 20 years. As gains have been made in treating joint disease in RA, our understanding of the impact of extra-articular manifestations of RA, such as cardiac and lung disease—specifically interstitial lung disease (ILD)—has gradually increased. While rheumatologists increasingly appreciate the…

Case Report: Rheumatoid Arthritis Complicated by Large Granular Lymphocytic Leukemia

Nam D. Nguyen, DO (Maj., USAF, MC), Erica Hill, DO (Lt. Col., USAF, MC), & Jay Higgs, MD (Col. [ret], USAF, MC)  |  

Large granular lymphocytic (LGL) leukemia is a rare, chronic, lymphoproliferative disorder of cytotoxic T cell or natural killer cell lineage with an annual incidence of 0.72 cases per 1 million people in the U.S.1 The most common sub­type of LGL leukemia, T-LGL leukemia, follows an indolent disease course and accounts for approximately 85% of cases….

The Dual-Target Strategy in Rheumatoid Arthritis: Put Patients First

Ricardo J.O. Ferreira, RN, PhD; Leonard H. Calabrese, DO; & José A.P. Da Silva, MD, PhD  |  

The impressive progress of medical knowledge and technology reinforces our trust in the scientific methodology that made it all possible. However, that progress also creates risks related to the primary goal of medical care: to serve our patients’ interests and enjoyment of life in the best possible way. In this article we present our views…